Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Mean cost-effectiveness of ICU admission versus hypothetical general ward care. Data from Norway*

From: Costs and expected gain in lifetime health from intensive care versus general ward care of 30,712 individual patients: a distribution-weighted cost-effectiveness analysis

Patient group ICU strategy Costs Incremental costs QALYs Incremental QALYs Incremental C/E Prob C/Ea Distr C/Eb
All (n = 30,712)
  Reject 16,100   6.1 (11.6)     
  Admit 34,800 18,700 7.7 (14.4) 1.6 (2.8) 11,600 0.95 5000
Medical (n = 17122)
  Reject 15,300   5.7 (10.9)     
  Admit 33,500 18,200 7.4 (13.8) 1.7 (2.9) 10,700 0.97 4600
Acute surgery (n = 9722)
  Reject 16,200   6.5 (12.9)     
  Admit 36,900 20,700 8.2 (15.8) 1.7 (2.9) 12,300 0.93 5400
Planned surgery (n = 3868)
  Reject 19,200   6.6 (11.5)     
  Admit 35,400 16,200 7.7 (13.4) 1.1 (1.9) 14,700 0.84 6500
  1. * The numbers are average extra costs in Euro or health gains in quality-adjusted life years (QALYs) per patient. Costs and QALYs were discounted at 4% annually (undiscounted QALYs in brackets)
  2. aUsing a general cost-effectiveness threshold of €22,000/QALY
  3. bResults after health gains were weighted according to the patient’s lifetime QALYs in case of general ward care (severity of disease)
  4. C/E cost-effectiveness, Distr distribution-weighted, Prob probability
Back to article page